Journal article
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement
JAMA : the journal of the American Medical Association, Vol.318(22), pp.2224-2233
12/12/2017
DOI: 10.1001/jama.2017.18261
PMID: 29234814
Abstract
Menopause occurs at a median age of 51.3 years, and the average US woman who reaches menopause is expected to live another 30 years. The prevalence and incidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and breast cancer, increase with age; however, the excess risk for these conditions that can be attributed to menopause alone is uncertain. Since the publication of findings from the Women's Health Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy has declined.
To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on the use of menopausal hormone therapy for the primary prevention of chronic conditions.
The USPSTF reviewed the evidence on the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal women and whether outcomes vary among women in different subgroups or by timing of intervention after menopause. The review did not address hormone therapy for preventing or treating menopausal symptoms.
Although the use of hormone therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, there are also well-documented harms. The USPSTF determined that the magnitude of both the benefits and the harms of hormone therapy in postmenopausal women is small to moderate. Therefore, the USPSTF concluded with moderate certainty that combined estrogen and progestin has no net benefit for the primary prevention of chronic conditions for most postmenopausal women with an intact uterus and that estrogen alone has no net benefit for the primary prevention of chronic conditions for most postmenopausal women who have had a hysterectomy.
The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy. (D recommendation).
Details
- Title: Subtitle
- Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement
- Creators
- David C Grossman - Kaiser Permanente Washington Health Research InstituteSusan J Curry - University of IowaDouglas K Owens - Stanford UniversityMichael J Barry - Harvard UniversityKarina W Davidson - Columbia UniversityChyke A Doubeni - University of PennsylvaniaJohn W Epling Jr - Virginia TechAlex R Kemper - Nationwide Children's HospitalAlex H Krist - Virginia Commonwealth UniversityAnn E Kurth - Yale UniversityC Seth Landefeld - University of Alabama at BirminghamCarol M Mangione - University of California, Los AngelesMaureen G Phipps - Brown UniversityMichael Silverstein - Boston UniversityMelissa A Simon - Northwestern UniversityChien-Wen Tseng - Honolulu UniversityUS Preventive Services Task Force
- Resource Type
- Journal article
- Publication Details
- JAMA : the journal of the American Medical Association, Vol.318(22), pp.2224-2233
- DOI
- 10.1001/jama.2017.18261
- PMID
- 29234814
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- Language
- English
- Date published
- 12/12/2017
- Academic Unit
- Health Management and Policy; Community and Behavioral Health
- Record Identifier
- 9984366294302771
Metrics
6 Record Views